$CLNN News

Clene Q1 EPS $(0.69) Misses $(0.66) Estimate, Sales $15.000K Miss $35.064K Estimate

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target

Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug

Clene Announces FDA Approves Propose Data To Be Capable for Submission, Review Of New Drug Application For Pathway To Treat Amyotrophic Lateral Sclerosis

Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

Clene Q4 EPS $(0.88) Misses $(0.56) Estimate, Sales $77.000K Beat $49.000K Estimate

Clene Touts FDA Path for ALS Drug CNM-Au8, Highlights Biomarkers, Extends Cash Runway

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream

Clene to Present at the Emerging Growth Conference

When Will Clene Inc. (NASDAQ:CLNN) Turn A Profit?

Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2

Clene to Present at the Emerging Growth Conference

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

Clene Announces FDA Grants In-Person Type C Meeting In Q1 2026 As New Analyses Support NfL Reduction And CNM‑Au8 Biomarker Findings Linked To Lower ALS Mortality Risk

Clene Announces Registered Direct Offering of Over $28 Million

D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target

Clene Commences $28M Offering Of Securities

Clene to Present at the Emerging Growth Conference

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®